|
| Press Releases |
|
 |
|
| Wednesday, May 20, 2015 |
|
|
Eisai Launches In-house Developed Novel Anticancer Agent Lenvima (Lenvatinib Mesylate) as Treatment for Unresectable Thyroid Cancer in Japan |
| Eisai Co., Ltd. announced that it has launched its in-house developed novel anticancer agent Lenvima Capsule 4 mg and 10 mg as a treatment for unresectable thyroid cancer in Japan on May 20, 2015. more info >> |
|
| Thursday, May 14, 2015 |
|
|
Eisai to Present New Research on Oncology Products and Pipeline at 51st ASCO Annual Meeting |
Eisai Co., Ltd. announced today that a series of abstracts highlighting new study results on Halaven and Lenvima will be presented during the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, the United States, from May 29 to June 2, 2015.
more info >> |
|
| Monday, April 27, 2015 |
|
|
Eisai and Nihon Medi-Physics Enter Collaboration Agreement to Contribute to Diagnosis and Treatment of Dementia with Lewy Bodies |
| Eisai Co., Ltd. and Nihon Medi-Physics Co., Ltd. announced today that they have entered into a collaboration agreement to contribute to the diagnosis and treatment of dementia with Lewy bodies (DLB) in Japan. more info >> |
|
| Monday, April 13, 2015 |
|
|
Eisai and Genomics Plc to Collaborate in Analyses of Large-Scale Genotype/Phenotype Data to Inform Drug Development |
| Eisai Co., Ltd. and Genomics plc announced today that they have entered into a collaborative agreement to use Genomics' sophisticated statistical analyses of large-scale multi-phenotype genetic association data to inform Eisai's drug discovery process, including target selection, target validation, indication selection and repositioning. more info >> |
|
| Friday, April 3, 2015 |
|
|
Niigata University and Eisai Present Results of Joint Research in U.S. Academic Journal |
| A research group led by Professor Takeshi Ikeuchi of the Department of Molecular Genetics within the Brain Research Institute at Niigata University and Eisai Co., Ltd. announced today that the amount of plasma desmosterol was found to be highly correlated with longitudinal cognitive decline in patients with Alzheimer's disease. more info >> |
|
| Thursday, March 5, 2015 |
|
|
Eisai and Merck Enter Collaboration to Explore Novel Combination Regimens of Anti-PD-1 Therapy with Multi-targeting RTK Inhibitor and Microtubule Dynamics Inhibitor in Multiple Types of Cancer |
Eisai Co., Ltd. and Merck announced today a clinical trial collaboration to evaluate the safety, tolerability and efficacy of Merck's anti-D-1 therapy, pembrolizumab in combination with Eisai oncology compounds lenvatinib mesylate and eribulin mesylate in multiple clinical trials.
more info >> |
|
| Tuesday, March 3, 2015 |
|
|
China JSFDA Accepts Eisai's Application Seeking Additional Indication of Severe Alzheimer's Disease for Aricept |
| Eisai Co., Ltd. announced today that its New Drug Application for the additional indication of severe Alzheimer's Disease (AD) for Aricept(R) has been accepted for review by the Jiangsu Food and Drug Administration in China. more info >> |
|
| Monday, March 2, 2015 |
|
|
Eisai Launches Anticancer Agent Lenvima in the United States |
| Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has launched its in-house developed novel anticancer agent Lenvima (lenvatinib mesylate) as a treatment for locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer in the United States on February 26, 2015. more info >> |
|
| Wednesday, February 25, 2015 |
|
|
Eisai to Establish Oral Solid Dose Production Facility at New Suzhou Plant in China |
| Eisai Co., Ltd. announced today that its Chinese subsidiary, Eisai China Inc. (ECI) has decided to build a new oral solid dose (OSD) production facility at the site of its new Suzhou plant ("New Plant") located within the Suzhou Industrial Park in order to relocate and expand its existing OSD production facility ("Old Plant") within the same industrial park. more info >> |
|
|
Eisai Announces Phase III Trial of Anticancer Agent Halaven in Soft Tissue Sarcoma Shows Overall Survival Benefit in Primary Endpoint |
| Eisai Co., Ltd. announced today that in a Phase III clinical trial (Study 309) of its in-house discovered and developed anticancer agent eribulin mesylate in patients with soft tissue sarcomas, eribulin demonstrated a statistically significant extension in overall survival (OS) over the comparator treatment dacarbazine, and the study met its primary endpoint. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
DK88 Casino Officially Launches in Malaysia 
Feb 21, 2026 21:50 HKT/SGT
|
|
|
Graphene Manufacturing Group and Tickford Racing Unite to Push Performance Efficiency On and Off the Track
Feb 20, 2026 20:59 HKT/SGT
|
|
|
Full Convertible Bond Conversion Removes Overhang and Signals Valuation Reassessment for Shoucheng Holdings
Feb 20, 2026 20:32 JST
|
|
|
Investee Companies Take the National Stage: Shoucheng Holdings' 'Capital+Scenario+Industry Chain' Strategy Validated, Entering the Value Realization Phase
Feb 20, 2026 20:06 JST
|
|
|
Hong Kong designer labels shine at London Fashion Week
Feb 20, 2026 17:04 HKT/SGT
|
|
|
Spritzer EcoPark Champions Inclusive Experiences in Nature Through Meaningful Community Engagement
Feb 20, 2026 15:37 HKT/SGT
|
|
|
Shoucheng Holdings Draws Focus After Portfolio Companies Appear in Spring Festival Gala Robotics Showcase
Feb 20, 2026 15:29 HKT/SGT
|
|
|
Hitachi Rail Invests C$30 Million in New Canadian Headquarters
Feb 20, 2026 12:20 JST
|
|
|
The Capital Architect Behind the Gala Robots: Shoucheng Holdings (0697.HK) Enters a Milestone Year of Value Re-rating
Feb 20, 2026 09:11 HKT/SGT
|
|
|
Toyota Launches New RAV4 (PHEV) in Japan
Feb 19, 2026 19:25 JST
|
|
|
Osaka Hospital launches project to safely utilize generative AI for healthcare workforce improvements
Feb 19, 2026 12:12 JST
|
|
|
Asia's Protein Buyers Still Trail Global Best Practice -- But Momentum is Building, New ARE Benchmark Finds
Feb 19, 2026 11:02 HKT/SGT
|
|
|
CDAO Sydney 2026 Announces Two-Day, Co Located Event Series Uniting Australia's Senior Data & AI Leaders
Feb 18, 2026 17:17 HKT/SGT
|
|
|
India's Power Transition Creates Clear Utility Divide
Feb 18, 2026 16:00 HKT/SGT
|
|
|
MHI Machinery Systems Participates in Ramp Merging Support Demonstration Experiment for Autonomous Vehicles on the Tokyo Metropolitan Expressway
Feb 18, 2026 15:37 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
